Petros Pharmaceuticals, Inc.
PTPI
$0.0301
$0.00269.46%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 725.40K | 1.58M | 1.42M | 1.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 725.40K | 1.58M | 1.42M | 1.39M |
| Cost of Revenue | -- | 264.80K | 287.00K | 329.10K | -- |
| Gross Profit | -- | 460.60K | 1.29M | 1.09M | -- |
| SG&A Expenses | 1.46M | 1.45M | 2.30M | 2.29M | 1.50M |
| Depreciation & Amortization | -- | 656.10K | 739.40K | 717.80K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.46M | 2.47M | 3.92M | 3.70M | 1.50M |
| Operating Income | -1.46M | -1.75M | -2.34M | -2.28M | -1.50M |
| Income Before Tax | -1.20M | -9.27M | -2.22M | -662.00K | 382.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.20M | -9.27M | -2.22M | -662.00K | 382.90K |
| Earnings from Discontinued Operations | -1.06M | -- | -- | -- | -2.55M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.26M | -9.27M | -2.22M | -662.00K | -2.16M |
| EBIT | -1.46M | -1.75M | -2.34M | -2.28M | -1.50M |
| EBITDA | -750.50K | -1.09M | -1.60M | -1.56M | -785.10K |
| EPS Basic | -9.37 | -26.68 | -13.34 | -9.25 | -42.19 |
| Normalized Basic EPS | -0.65 | -9.75 | -3.53 | -1.40 | 1.26 |
| EPS Diluted | -9.37 | -26.68 | -13.34 | -9.25 | -42.19 |
| Normalized Diluted EPS | -0.65 | -9.75 | -3.53 | -1.40 | 1.26 |
| Average Basic Shares Outstanding | 1.16M | 404.30K | 393.20K | 295.50K | 190.30K |
| Average Diluted Shares Outstanding | 1.16M | 404.30K | 393.20K | 295.50K | 190.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |